Diğdem Göverti1, Nihan Büyüklüoğlu2, Hasan Kaya2, Rabia Nazik Yüksel2, Çiğdem Yücel3, Erol Göka2. 1. Department of Psychiatry, University of Health Sciences, Erenkoy Mental Health and Neurologic Disorders Training and Research Hospital, Istanbul, Turkey. digdem.goverti@gmail.com. 2. Department of Psychiatry, University of Health Sciences, Ankara City Hospital, Ankara, Turkey. 3. Department of Biochemistry, University of Health Sciences, Gulhane Training and Research Hospital, Ankara, Turkey.
Abstract
BACKGROUND: Neuronal pentraxin-2 (NPTX2, an immediate-early gene), which regulates synapse activity and neuroplasticity, plays an essential role in the neurodevelopmental process. NPTX2 possibly enhances the accumulation of amino-3-hydroxy-5-methyl-4-isoxazolepropionic receptors (AMPAR) on the postsynaptic membranes and stimulates excitatory synaptogenesis. We aimed to evaluate the plasma concentrations of NPTX2 of patients with schizophrenia in acute psychotic episodes compared with matched community-based controls. METHODS: Ninety-three (93) patients diagnosed with schizophrenia according to DSM-5 and 83 healthy controls were included. The patients, all of which were in acute psychotic episodes, were recruited from the inpatient clinic. The patients were assessed by the Positive and Negative Syndrome Scale (PANSS) and Clinical Global Impression- Severity (CGIS) scale, whereas the healthy subjects were evaluated with Structured Clinical Interview for DSM-5 (SCID-5) to exclude any major psychiatric diagnoses. RESULTS: NPTX2 serum concentrations were significantly higher in the schizophrenia group (p < 0.001). NPTX2 levels negatively correlated with age (p = 0.004) and PANSS-positive symptom scores (p < 0.001). The most determinant factors in predicting the change in NPTX2 levels were PANSS-positive symptom and general psychopathology scores. CONCLUSIONS: We conclude that NPTX2 could be involved in schizophrenia pathophysiology and valuable as a synapse-derived and glutamate-related biomarker. Further studies in larger samples assessing NPTX2 levels in remitted schizophrenia patients and combining neuroimaging techniques and cognitive evaluations with blood samples are needed.
BACKGROUND: Neuronal pentraxin-2 (NPTX2, an immediate-early gene), which regulates synapse activity and neuroplasticity, plays an essential role in the neurodevelopmental process. NPTX2 possibly enhances the accumulation of amino-3-hydroxy-5-methyl-4-isoxazolepropionic receptors (AMPAR) on the postsynaptic membranes and stimulates excitatory synaptogenesis. We aimed to evaluate the plasma concentrations of NPTX2 of patients with schizophrenia in acute psychotic episodes compared with matched community-based controls. METHODS: Ninety-three (93) patients diagnosed with schizophrenia according to DSM-5 and 83 healthy controls were included. The patients, all of which were in acute psychotic episodes, were recruited from the inpatient clinic. The patients were assessed by the Positive and Negative Syndrome Scale (PANSS) and Clinical Global Impression- Severity (CGIS) scale, whereas the healthy subjects were evaluated with Structured Clinical Interview for DSM-5 (SCID-5) to exclude any major psychiatric diagnoses. RESULTS: NPTX2 serum concentrations were significantly higher in the schizophrenia group (p < 0.001). NPTX2 levels negatively correlated with age (p = 0.004) and PANSS-positive symptom scores (p < 0.001). The most determinant factors in predicting the change in NPTX2 levels were PANSS-positive symptom and general psychopathology scores. CONCLUSIONS: We conclude that NPTX2 could be involved in schizophrenia pathophysiology and valuable as a synapse-derived and glutamate-related biomarker. Further studies in larger samples assessing NPTX2 levels in remitted schizophrenia patients and combining neuroimaging techniques and cognitive evaluations with blood samples are needed.
Authors: Emma L van der Ende; Meifang Xiao; Desheng Xu; Jackie M Poos; Jessica L Panman; Lize C Jiskoot; Lieke H Meeter; Elise Gp Dopper; Janne M Papma; Carolin Heller; Rhian Convery; Katrina Moore; Martina Bocchetta; Mollie Neason; Georgia Peakman; David M Cash; Charlotte E Teunissen; Caroline Graff; Matthis Synofzik; Fermin Moreno; Elizabeth Finger; Raquel Sánchez-Valle; Rik Vandenberghe; Robert Laforce; Mario Masellis; Maria Carmela Tartaglia; James B Rowe; Christopher R Butler; Simon Ducharme; Alex Gerhard; Adrian Danek; Johannes Levin; Yolande Al Pijnenburg; Markus Otto; Barbara Borroni; Fabrizio Tagliavini; Alexandre de Mendonca; Isabel Santana; Daniela Galimberti; Harro Seelaar; Jonathan D Rohrer; Paul F Worley; John C van Swieten Journal: J Neurol Neurosurg Psychiatry Date: 2020-04-09 Impact factor: 10.154
Authors: Andrew D Chang; Punit V Vaidya; Edward P Retzbach; Sunho J Chung; Urian Kim; Kathryn Baselice; Kristen Maynard; Alec Stepanian; Melissa Staley; Lan Xiao; Ashley Blouin; Sungho Han; JongAh Lee; Paul F Worley; Kellie L Tamashiro; Barbara L Hempstead; Keri Martinowich; Mary Ann Wilson; Jay M Baraban; Irving M Reti Journal: Neuropsychopharmacology Date: 2017-10-20 Impact factor: 8.294